دورية أكاديمية
أعرض في EDS

Imaging GRPr Expression in Metastatic Castration-Resistant Prostate Cancer with [ 68 Ga]Ga-RM2-A Head-to-Head Pilot Comparison with [ 68 Ga]Ga-PSMA-11.

التفاصيل البيبلوغرافية
العنوان: Imaging GRPr Expression in Metastatic Castration-Resistant Prostate Cancer with [ 68 Ga]Ga-RM2-A Head-to-Head Pilot Comparison with [ 68 Ga]Ga-PSMA-11.
المؤلفون: Fernández R; Nuclear Medicine and PET/CT Center PositronMed, Providencia, Santiago 7501068, Chile., Soza-Ried C; Nuclear Medicine and PET/CT Center PositronMed, Providencia, Santiago 7501068, Chile.; Positronpharma SA, Providencia, Santiago 7501068, Chile., Iagaru A; Department of Radiology, Division of Nuclear Medicine and Molecular Imaging, Stanford University, Stanford, CA 94305, USA., Stephens A; Life Molecular Imaging GmbH, 13353 Berlin, Germany., Müller A; Life Molecular Imaging GmbH, 13353 Berlin, Germany., Schieferstein H; Formerly Piramal Imaging GmbH, 13353 Berlin, Germany.; Merck Healthcare KGaA, 64293 Darmstadt, Germany., Sandoval C; Fundación Arturo López Pérez, Providencia, Santiago 750069, Chile., Amaral H; Nuclear Medicine and PET/CT Center PositronMed, Providencia, Santiago 7501068, Chile.; Positronpharma SA, Providencia, Santiago 7501068, Chile., Kramer V; Nuclear Medicine and PET/CT Center PositronMed, Providencia, Santiago 7501068, Chile.; Positronpharma SA, Providencia, Santiago 7501068, Chile.
المصدر: Cancers [Cancers (Basel)] 2023 Dec 29; Vol. 16 (1). Date of Electronic Publication: 2023 Dec 29.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Background: The gastrin-releasing peptide receptor (GRPr) is highly overexpressed in several solid tumors, including treatment-naïve and recurrent prostate cancer. [ 68 Ga]Ga-RM2 is a well-established radiotracer for PET imaging of GRPr, and [ 177 Lu]Lu-RM2 has been proposed as a therapeutic alternative for patients with heterogeneous and/or low expression of PSMA. In this study, we aimed to evaluate the expression of GRPr and PSMA in a group of patients diagnosed with castration-resistant prostate cancer (mCRPC) by means of PET imaging.
Methods: Seventeen mCRPC patients referred for radio-ligand therapy (RLT) were enrolled and underwent [ 68 Ga]Ga-PSMA-11 and [ 68 Ga]Ga-RM2 PET/CT imaging, 8.8 ± 8.6 days apart, to compare the biodistribution of each tracer. Uptake in healthy organs and tumor lesions was assessed by SUV values, and tumor-to-background ratios were analyzed.
Results: [ 68 Ga]Ga-PSMA-11 showed significantly higher uptake in tumor lesions in bone, lymph nodes, prostate, and soft tissues and detected 23% more lesions compared to [ 68 Ga]Ga-RM2. In 4/17 patients (23.5%), the biodistribution of both tracers was comparable.
Conclusions: Our results show that in our cohort of mCRPC patients, PSMA expression was higher compared to GRPr. Nevertheless, RLT with [ 177 Lu]Lu-RM2 may be an alternative treatment option for selected patients or patients in earlier disease stages, such as biochemical recurrence.
References: J Nucl Med. 2007 Jan;48(1):88-93. (PMID: 17204703)
J Nucl Med. 2023 Oct;64(10):1654-1659. (PMID: 37934025)
J Nucl Med. 2017 Dec;58(12):1883-1884. (PMID: 28970333)
J Nucl Med. 2023 Apr;64(4):592-597. (PMID: 36328488)
N Engl J Med. 2021 Sep 16;385(12):1091-1103. (PMID: 34161051)
Cells. 2018 Aug 29;7(9):. (PMID: 30158439)
J Exp Clin Cancer Res. 2022 Feb 2;41(1):46. (PMID: 35109899)
Diagnostics (Basel). 2021 Nov 09;11(11):. (PMID: 34829417)
Clin Cancer Res. 1997 Jan;3(1):81-5. (PMID: 9815541)
Prostate. 2014 May;74(6):659-68. (PMID: 24464532)
J Nucl Med. 2017 Feb;58(2):293-299. (PMID: 27609789)
Oncotarget. 2015 Sep 8;6(26):22513-25. (PMID: 26068968)
PLoS One. 2021 May 10;16(5):e0251375. (PMID: 33970962)
Adv Radiat Oncol. 2018 Oct 23;3(4):693-700. (PMID: 30370371)
World J Urol. 2003 Aug;21(3):183-7. (PMID: 12845460)
Eur J Nucl Med Mol Imaging. 2020 Jan;47(1):123-135. (PMID: 31482426)
Hum Pathol. 2007 May;38(5):696-701. (PMID: 17320151)
Curr Pharm Des. 2013;19(18):3329-41. (PMID: 23431995)
Int J Mol Sci. 2013 Feb 21;14(2):4298-316. (PMID: 23429271)
EJNMMI Res. 2020 Jun 12;10(1):62. (PMID: 32533273)
Front Oncol. 2023 Aug 31;13:1199432. (PMID: 37719014)
Bioconjug Chem. 2012 Apr 18;23(4):688-97. (PMID: 22369515)
J Nucl Med. 2017 Jan;58(1):75-80. (PMID: 27493272)
Prostate. 2009 Jul 1;69(10):1101-8. (PMID: 19343734)
J Nucl Med. 2021 Nov;62(11):1545-1549. (PMID: 33674398)
Nat Rev Urol. 2013 Apr;10(4):235-44. (PMID: 23507930)
Prostate. 1994 Jul;25(1):29-38. (PMID: 8022709)
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1014-1024. (PMID: 28283702)
Eur J Nucl Med Mol Imaging. 2011 Jan;38(1):97-107. (PMID: 20717822)
Eur J Nucl Med Mol Imaging. 2016 May;43(5):964-973. (PMID: 26631238)
Pharmacol Rev. 2008 Mar;60(1):1-42. (PMID: 18055507)
Cancers (Basel). 2021 Dec 03;13(23):. (PMID: 34885214)
J Nucl Med. 2015 Jul;56(7):1003-1010. (PMID: 26069305)
J Nucl Med. 2016 Sep;57(9):1334-8. (PMID: 27056618)
Ann Nucl Med. 2016 Oct;30(8):588-92. (PMID: 27246952)
Eur J Nucl Med Mol Imaging. 2023 Nov;50(13):4087-4095. (PMID: 37555901)
J Nucl Med. 2018 May;59(5):803-808. (PMID: 29084827)
Front Oncol. 2020 Sep 03;10:1630. (PMID: 33014819)
Neoplasma. 2012;59(2):224-32. (PMID: 22248281)
J Nucl Med. 2019 Mar;60(3):362-368. (PMID: 30042163)
Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1448-1454. (PMID: 28488028)
Eur Urol. 2017 Feb;71(2):151-154. (PMID: 27477525)
Behav Res Methods. 2007 May;39(2):175-91. (PMID: 17695343)
Cancer Res. 1999 Mar 1;59(5):1152-9. (PMID: 10070977)
J Nucl Med. 2016 Apr;57(4):557-62. (PMID: 26659347)
Mol Imaging Biol. 2018 Aug;20(4):501-509. (PMID: 29256046)
Mol Med Rep. 2018 Oct;18(4):3547-3554. (PMID: 30106145)
Pathol Oncol Res. 2009 Jun;15(2):167-72. (PMID: 18802790)
Nat Cancer. 2020 Nov;1(11):1041-1053. (PMID: 34258585)
J Nucl Med. 2022 Dec;63(12):1829-1835. (PMID: 35552245)
Lancet Oncol. 2018 Jun;19(6):825-833. (PMID: 29752180)
J Nucl Med. 2015 May;56(5):668-74. (PMID: 25791990)
Prostate. 2012 Feb;72(3):318-25. (PMID: 21739464)
Case Rep Oncol. 2016 Aug 17;9(2):457-463. (PMID: 27721768)
J Nucl Med. 2020 Dec;61(12):1749-1755. (PMID: 32332143)
Eur Radiol. 2023 Jan;33(1):472-482. (PMID: 35864350)
J Nucl Med. 2023 May;64(5):744-750. (PMID: 36396456)
Mol Cancer Res. 2012 Feb;10(2):230-8. (PMID: 22172337)
Eur Urol. 2023 Oct 25;:. (PMID: 37891072)
فهرسة مساهمة: Keywords: GRPr; PET imaging; PSMA; [68Ga]Ga-PSMA-11; [68Ga]Ga-RM2; mCRPC
تواريخ الأحداث: Date Created: 20240111 Latest Revision: 20240114
رمز التحديث: 20240114
مُعرف محوري في PubMed: PMC10778208
DOI: 10.3390/cancers16010173
PMID: 38201600
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers16010173